Jump to: navigation, search

JX-594 is name of an oncolytic poxvirus engineered for replication, transgene expression and amplification in cancer cells [1].

The abilities of the specially engineered viruses were under research since beginning of century 21 [2][3].

The positive effect of JX-594 on the reduction of the growth of the cancer tissues is reported to be statistically–significant.


  1. http://www.nature.com/nature/journal/v477/n7362/full/nature10358.html C.J.Breitbach, J.Burke, D.Jonker, J.Stephenson, A.R.Haas, L.Q.M.Chow, J.Nieva, T.-H.Hwang, A.Moon, R.Patt, A.Pelusio, F.Boeuf, J.Burns, L.Evgin, N.D.Silva, S.Cvancic, T.Robertson, J.E.Je, Y.S.Lee, K.Parato, J.-S.Diallo, A.Fenster, M.Daneshmand, J.C.Bell, D.H.Kirn. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477, 99–102 (01 September 2011)
  2. http://www.nature.com/mt/journal/v15/n9/full/6300215a.html C.J.Breitbach, J.M.Paterson, C.G.Lemay, T.J.Falls, A.McGuire, K.A.Parato, D.F.Stojdl, M.Daneshmand, K.Speth, D.Kirn, J.A.McCart, H.Atkins, J.C.Bell. Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow. Molecular Therapy (2007) 15 9, 1686–1693
  3. http://www.nature.com/mt/journal/v16/n9/full/mt2008143a.html T.-C.Liu, T.Hwang, B.-H.Park, J.Bell, D.H.Kirn. The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma. Molecular Therapy (2008) 16 9, 1637–1642